SVR24 rates in patients with HCV genotype 5 and 6 infection treated with peginterferon alfa-2a (40KD) plus ribavirin: results from the real world PROPHeSYS study
François D’heygere,
Christophe George,
François Habersetzer,
Davender Tripathi,
Calvin Q. Pan,
Jose A. Giron,
Manuela Schmitz,
Fernando Tatsch
Affiliations
François D’heygere
Department of Gastroenterology and Hepatology, AZ Groeninge Hospital, Kortrijk, Belgium; Correspondence and reprint request:
Christophe George
Department of Gastroenterology and Hepatology, AZ Groeninge Hospital, Kortrijk, Belgium
François Habersetzer
Pôle Hépato-digestif, Unité Inserm U.1110, Université de Strasbourg, Laboratoire d’Excellence HepSys, Strasbourg, France
Davender Tripathi
Southlake Regional Health Centre, Newmarket, ON, Canada
Calvin Q. Pan
Division of Gastroenterology, Department of Medicine, NYU Langone Medical Center, New York University School of Medicine, New York, NY, USA
Jose A. Giron
Orlando Infectious Disease Center, Orlando, FL, USA
